Diisopropylethylamine → 5-{[(3S)-1-(4-morpholinylcarbonyl)-3-pyrrolidinyl]methyl}-4-[4-(7-quinolinyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
Reaction equation
Cl.[NH:2]1[CH2:6][CH2:5][C@@H:4]([CH2:7][C:8]2[N:9]([C:14]3[CH:19]=[CH:18][C:17]([C:20]4[CH:29]=[C:28]5[C:23]([CH:24]=[CH:25][CH:26]=[N:27]5)=[CH:22][CH:21]=4)=[CH:16][CH:15]=3)[C:10](=[O:13])[NH:11][N:12]=2)[CH2:3]1.C(N(CC)C(C)C)(C)C.[N:39]1([C:45](Cl)=[O:46])[CH2:44][CH2:43][O:42][CH2:41][CH2:40]1>ClCCl>[N:39]1([C:45]([N:2]2[CH2:6][CH2:5][C@@H:4]([CH2:7][C:8]3[N:9]([C:14]4[CH:15]=[CH:16][C:17]([C:20]5[CH:29]=[C:28]6[C:23]([CH:24]=[CH:25][CH:26]=[N:27]6)=[CH:22][CH:21]=5)=[CH:18][CH:19]=4)[C:10](=[O:13])[NH:11][N:12]=3)[CH2:3]2)=[O:46])[CH2:44][CH2:43][O:42][CH2:41][CH2:40]1Participants
5
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
Into a 4 mL vial was placed 5-[(3S)-3-pyrrolidinylmethyl]-4-[4-(7-quinolinyl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one hydrochloride (0.147 mmol). Added in succession was dichloromethane (2 mL), N,N-diisopropylethylamine (0.458 mmol), and 4-morpholinecarbonyl chloride (0.157 mmol). The vial was capped and the solution was stirred at room temperature for 30 min. The solution was concentrated in vacuo. Reverse phase HPLC (10-70% acetonitrile/water+0.1% NH4OH) was utilized in purifying the title compound (23 mg, 31%). MS(ES)+ m/e 485.2 [M+H]+.
Workup
- additionAdded in succession
- customThe vial was capped
- concentrationThe solution was concentrated in vacuo
- customin purifying the title compound (23 mg, 31%)
Sources & evidence
- ORD record
- ord-b5e4864c9e94404eb9015e89af7ea085
- Source dataset
- uspto-grants-2016_05
- Patent number
- US09340529B2
Reaction notes
Loading…